U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research | CDER
  5. Office of Neuroscience - Division of Neurology I
  1. Center for Drug Evaluation and Research | CDER

Office of Neuroscience - Division of Neurology I

The Office of New Drugs is undergoing a reorganization. This site will be updated in the near future.  Please check back often.  For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. Until this page is updated, please use the current contact information presented on this page or contact druginfo@fda.hhs.gov if you have additional questions.

The Division of Neurology I (DNI) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of neurological diseases and conditions, such as Alzheimer’s disease, stroke, Parkinson’s disease, Huntington’s disease, epilepsy, migraine headaches, muscular dystrophy, amyotrophic lateral sclerosis, multiple sclerosis, dementia, and narcolepsy. 

  • Director: Eric Bastings, M.D (Acting)
  • Deputy Director for Safety: Alice Hughes, M.D.
  • Safety Regulatory Project Manager: Christine Phipps, Pharm.D.
  • Regulatory Operations Chief, Project Management Staff: Jacqueline Ware, Pharm.D.

Contact Us

Mailing Address: 
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4346
Phone: (301) 796-2250
Fax: (301) 796-9842